NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease

Active Not RecruitingPhase 1

Sponsor: Tharick Pascoal

Conditions: Alzheimer Disease

Interventions: 18F-Flortaucipir radiopharmaceutical, 18F-MK-6240 radiopharmaceutical, Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol)

Countries: United States, Canada, Spain

The purpose of this study is to compare/harmonize cross-sectional and longitudinal tau tangle measurements obtained with the tau PET radiopharmaceuticals Flortaucipir and MK-6240 to elucidate the advantages and caveats of their use in clinical trials/practice and provide parameters to integrate their estimates.

Eligibility overview

Sex: ALL

Age: 18 Years to 90 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion criteria:

* Have a study partner who will be able to provide an independent evaluation of functioning.
* Willing and capable of undergoing repeated MR/PET imaging.
* Fluent in a language approved by the coordinating center.
* At screening, must have no cognitive impairment, or meet criteria for single- or multiple-domain amnestic mild cognitive impairment or Alzheimer's disease dementia.

Exclusion criteria:

* Inability to provide informed consent by self or by proxy.
* Pregnant or breastfeeding women.
* Have any condition or are taking any medication that could increase the risk to the participant, limit the ability to tolerate or interfere with the results of the tests and procedures (in the opinion of the investigator).

Locations (9)

Berkeley, California, United States
San Francisco, California, United States
Rochester, Minnesota, United States
St Louis, Missouri, United States
Pittsburgh, Pennsylvania, United States
Providence, Rhode Island, United States
Houston, Texas, United States
Montreal, Quebec, Canada
Barcelona, Spain, Spain